Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



GSK's Withdrawn Myeloma Drug Could Receive Combo Approval

November 27, 2024
Pharmaceutical company GSK is considering seeking combination approval for a previously withdrawn drug used in the treatment of multiple myeloma. The drug, which was withdrawn due to safety concerns, has shown promising results in recent studies and could potentially have a significant impact on the treatment of this rare form of cancer. GSK is exploring options to reintroduce the drug in combination with other therapies in order to increase its efficacy and safety profile. Investors are recommended to consult professionals from Stocks Prognosis for a forecast on the movement of GSK's stocks.

Find out how the GSK PLC rate is expected to change

Get Forecast for GSK

Investor opinions & comments:

I hope this drug combination will have fewer safety concerns and provide better outcomes for patients
— from ProfitPam at 11-30-2024 20:27
I'm optimistic about the future prospects for this drug combination in treating multiple myeloma
— from BudgetBrad at 11-30-2024 03:12
It's encouraging to see GSK exploring options to reintroduce the drug to potentially help more patients
— from FinanceFiona at 11-29-2024 17:28
I'm not sure if GSK has thoroughly addressed the safety concerns that led to the drug's initial withdrawal
— from MilaWagner at 11-29-2024 17:16
This is great news for patients with multiple myeloma, as they may have a new treatment option
— from SmartSteve at 11-29-2024 16:51
This news could have a positive impact on GSK's stock performance
— from KevinWalker at 11-29-2024 15:12
I am curious to see what other therapies GSK plans to combine with the drug
— from SavingsSarah at 11-29-2024 12:33
I wonder what specific safety concerns led to the drug's withdrawal. It's important to understand potential risks
— from MilaWagner at 11-29-2024 01:38
I'm glad GSK is investing in research and development for rare forms of cancer
— from CharlesScott at 11-28-2024 16:50
I have confidence in GSK's ability to develop safe and effective treatments
— from StockSteve at 11-28-2024 03:58
Combining drugs can sometimes lead to higher costs and potential unknown side effects
— from WealthyWyatt at 11-28-2024 00:29
This could be a major breakthrough in the treatment of multiple myeloma
— from SmartSabrina at 11-27-2024 10:38
If you want to leave a comment, then you need Login or Register





Other news for GSK

GSKJune 2, 2025QuantWave Delivers 7.39% Profit with Successful GSK PLC Stock Price Target Forecast  ~2 min.

On March 21, 2025, QuantWave, the automated forecasting platform, signaled a long position for GSK PLC at a price of 38.79 $. Today, on June 2, 2025, the stock reached the predicted target price of 41....

GSKJune 2, 2025QuantWave Hits Price Target Forecast for GSK PLC, Yielding 8.78% Profit  ~1 min.

QuantWave, the automated forecasting platform, successfully achieved its price target forecast for GSK PLC, resulting in a profit of 8.78%....

GSKJune 2, 2025QuantWave Achieves GSK PLC Price Target Forecast with 6.93% Profit  ~1 min.

QuantWave, the leading automated forecasting platform, has successfully hit the price target forecast for GSK PLC, resulting in a profitable trade with a 6.93% gain....

GSKJune 2, 2025QuantWave Achieves 8.39% Profit Target Forecast for GSK PLC Stock  ~1 min.

QuantWave, an automated forecasting platform, has successfully hit a price target forecast for the stock of GSK PLC, resulting in a profit of 8.39%....

GSKJune 2, 2025QuantWave Achieves 11.28% Profit Target Forecast for GSK PLC  ~1 min.

QuantWave, the automated forecasting platform, successfully predicted a long position for GSK PLC on April 1, 2025, when the stock was trading at $37.44....



Related news

VRTXMarch 22, 2025Vertex Pharmaceuticals VRTX: One of the Best Biotech Stocks to Buy According to Billionaires  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX) has been recognized as one of the top biotech stocks to invest in by billionaires....

REGNJanuary 3, 2025Regeneron Pharmaceuticals: A Promising Future with Strong Returns  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making waves in the pharmaceutical industry with its groundbreaking research and innovative treatments....

VRTXJanuary 12, 2025Vertex Pharmaceuticals Incorporated Faces Setbacks in Clinical Trials  ~1 min.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares experienced a slide recently due to setbacks in its clinical trials....

PFENovember 21, 2024Pfizer Inc. Introduces Groundbreaking Immunotherapy Treatment, Boosting Confidence in PFE Stock  ~2 min.

Pfizer Inc., a leading pharmaceutical company, has announced the development of a groundbreaking immunotherapy treatment that could revolutionize cancer treatment....

REGNJanuary 2, 2025Regeneron Pharmaceuticals: Discoveries and Innovations Driving Growth  ~2 min.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been making significant strides in the pharmaceutical industry, driving growth and attracting investors....